UR8 Stock Chart & Stats
€36.40
€1.00(2.79%)
At close: 4:00 PM EDT
€36.40
€1.00(2.79%)
Day’s Range― - ―
52-Week Range€13.80 - €42.90
Previous CloseN/A
Volume22.00
Average Volume (3M)12.00
Market Cap
€1.77B
Enterprise Value€1.94K
Total Cash (Recent Filing)€107.97M
Total Debt (Recent Filing)€196.13M
Price to Earnings (P/E)―
Beta-0.54
Next Earnings
Nov 05, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,880,566
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.14Price Target Upside46.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.61
Revenue Forecast (FY)€276.80M
Bulls Say, Bears Say
Bulls Say
ZUSDURI Commercial MomentumZUSDURI is showing strong early commercial traction, with rapid revenue growth, broader account activation, and increasing repeat prescribing. These indicators suggest expanding physician confidence and treatment adoption, creating a potentially durable growth engine beyond the existing JELMYTO franchise.
Strong Revenue Growth And Gross MarginsThe combination of substantial revenue growth and consistently high gross margins indicates attractive product-level economics. If commercial expansion continues, the company should have meaningful gross profit available to support development and commercialization, although operating costs currently absorb that benefit.
Durable Clinical And IP PositionLong-term response durability supports the clinical value proposition of the franchise, while expected patent protection into 2044 can extend commercial exclusivity. Together, these factors may strengthen differentiation, preserve product economics, and support multiple future uro-oncology opportunities.
Bears Say
Persistent Operating LossesUroGen has not yet converted its strong gross-profit profile into sustainable earnings because operating expenses remain very large. Persistent deep losses reduce internally generated funding capacity and leave the company dependent on successful growth and eventual cost leverage to reach profitability.
Cash Burn And Funding RiskContinued operating and free-cash-flow consumption means the business is using substantial capital while it expands products and advances its pipeline. Unless losses narrow materially, ongoing funding needs could constrain investment choices and increase the consequences of execution delays or weaker-than-expected adoption.
Rising Leverage And Negative EquityNegative equity combined with materially higher debt signals limited balance-sheet flexibility. Rising leverage increases financial pressure while the company remains loss-making, and the associated interest burden can slow the path to profitability by absorbing cash that could otherwise support commercial or pipeline investment.
Urogen Pharma News
UR8 FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was €13.80 and its highest was €42.90 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is €1.77B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 34 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -€0.249 earnings per share for the quarter, missing the consensus estimate of -€0.236 by -€0.013.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.09.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,880,566 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -€0.249 in its last earnings report, missing expectations of -€0.236. Following the earnings report the stock price went up 2.677%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in DE:UR8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€53.14 (46.00% Upside)
€53.14 (46.00% Upside)
Blogger Sentiment
Bullish
DE:UR8 Sentiment 86%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
UR8 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all DE:UR8 earnings summariesUR8 Stock 12 Month Forecast
Average Price Target
€53.14
▲(46.00% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―